Wound botulism

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:178475A05.1
Who is this for?
Show terms as
1FDA treatments8Treatment centers1Financial resources

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Wound botulism is a rare but serious infectious disease caused by the bacterium Clostridium botulinum, which colonizes a wound and produces botulinum neurotoxin in vivo. Unlike foodborne botulism, the toxin is not ingested but rather produced locally at the site of an infected wound and then absorbed into the bloodstream. The toxin blocks the release of acetylcholine at neuromuscular junctions, leading to progressive descending flaccid paralysis. Wound botulism primarily affects the nervous system and skeletal muscles. It has become increasingly associated with injection drug use, particularly subcutaneous injection ("skin popping") of black tar heroin, as well as traumatic wounds and, rarely, surgical wounds. Key clinical features include cranial nerve palsies (diplopia, blurred vision, ptosis, dysarthria, dysphagia), symmetric descending weakness progressing from the head and neck to the trunk and extremities, and respiratory failure in severe cases. Unlike foodborne botulism, gastrointestinal symptoms such as nausea, vomiting, and diarrhea are typically absent. Patients may also present with a wound that appears infected, though the wound may sometimes appear deceptively benign. Fever may be present due to wound infection but is not caused by the toxin itself. The incubation period is typically 4 to 14 days after wound contamination. Treatment involves prompt administration of equine-derived heptavalent botulinum antitoxin to neutralize circulating toxin and prevent disease progression. Surgical debridement of the infected wound is essential to remove the source of toxin production, along with antibiotic therapy (typically penicillin or metronidazole) directed against Clostridium botulinum. Supportive care, including mechanical ventilation for respiratory failure, is often required. Recovery can take weeks to months as new nerve terminals must regenerate. Early recognition and treatment are critical, as delays in antitoxin administration are associated with worse outcomes and prolonged intensive care stays.

Also known as:

Clinical phenotype terms— hover any for plain English:

Cardiac arrestHP:0001695Diaphragmatic paralysisHP:0006597MydriasisHP:0011499
Age of Onset

Adult

Begins in adulthood (age 18 or older)

Orphanet ↗NORD ↗

Treatments

1 available

IMPAVIDO

miltefosine· Knight Therapeutics (USA)■ Boxed Warning

treatment of cutaneous leishmaniasis caused by Leishmania guyanensis

No actively recruiting trials found for Wound botulism at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Wound botulism community →

No specialists are currently listed for Wound botulism.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Financial Resources

1 resources
IMPAVIDO(miltefosine)Knight Therapeutics (USA)

Travel Grants

No travel grants are currently matched to Wound botulism.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Wound botulismForum →

No community posts yet. Be the first to share your experience with Wound botulism.

Start the conversation →

Latest news about Wound botulism

No recent news articles for Wound botulism.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Wound botulism

What is Wound botulism?

Wound botulism is a rare but serious infectious disease caused by the bacterium Clostridium botulinum, which colonizes a wound and produces botulinum neurotoxin in vivo. Unlike foodborne botulism, the toxin is not ingested but rather produced locally at the site of an infected wound and then absorbed into the bloodstream. The toxin blocks the release of acetylcholine at neuromuscular junctions, leading to progressive descending flaccid paralysis. Wound botulism primarily affects the nervous system and skeletal muscles. It has become increasingly associated with injection drug use, particularly

At what age does Wound botulism typically begin?

Typical onset of Wound botulism is adult. Age of onset can vary across affected individuals.